Alteplase In Preventing Posterior Capsule Opacity By Plasminogen Activator Inhibitor-1 And Type I Collagen Expression Inhibition In A Posterior Capsule Opacity Model With Fibrin Reaction In Vitro : A Experimental Laboratory Study

• Main Authors: Rina Wulandari, Rina, Indri Wahyuni, Indri, Arifa Mustika, Arifa, Windhu Purnomo, Windhu, Nurwasis, Nurwasis
• Format: Article PeerReviewed
• Language: English; English; Indonesian; English
• Published: DR. P. R. YADAV
• Subjects: R5-920 Medicine (General)
• Online Access: https://repository.unair.ac.id/120809/1/04%20artikel.pdf; https://repository.unair.ac.id/120809/2/04%20turnitin.pdf; https://repository.unair.ac.id/120809/3/04%20karil.pdf; https://repository.unair.ac.id/120809/8/Etik%20Alteplase%20In%20Preventing.pdf; https://repository.unair.ac.id/120809/; https://connectjournals.com/achivestoc2.php?fulltext=3066000H_4695-4701.pdf&&bookmark=CJ-033216&&issue_id=Supp-02&&yaer=2019
• Institution: Universitas Airlangga

Abstract To investigate the effect of alteplase on plasminogen activator inhibitor -1 (PAI-1) and type I collagen expression in a posterior capsule opacity (PCO) model with fibrin reaction in vitro. Cultured human lens epithelial cells (HLEC) were isolated from the anterior lens capsule following a capsulotomy during cataract surgery. Cultured HLEC went into an in vitro wound scratch assay on fibrin coated dishes and were then divided into 4 groups consisting of a FBS 10% control group, and treatment groups of alteplase 25, 50 and 100 μg/ml. The effect of alteplase on plasminogen activator inhibitor (PAI-1) and type I collagen expression in PCO and its reaction with fibrin was investigated, determined by fluorescein intensity, labelled with fluorescein isothiocyanate (FITC) antibody of PAI-1 and type I collagen. The difference between expression levels among the groups was analyzed using a Kolmogorov-Smirnov test followed by a posthoc test showing a significance level of p<0.05. The lowest PAI-1 expression was obtained in the group treated with alteplase 100 ìg /ml (1.26 × 106± 3.31 × 105) compared to the control group (6.27 × 106± 2.37 × 105 , p= 0.00); a significant result was also obtained among treatment groups, and showed that inhibition behaves in a dose dependent way. All treatment groups significantly inhibited type I collagen as compared to control group (3.54 × 106 ± 8.28 × 105, p= 0.00), but the result is not significantly different among treatment groups. The inhibition effect of PAI-1 and type I collagen were influenced from the affects of several another pathways in type I collagen synthesis other than PAI-1. Alteplase showed an inhibition effect on PAI-1 and type I collagen with fibrin reaction in vitro in anterior lens capsule fibrosis, despite the inhibition effect on type I collagen not aligning with the inhibition of PAI-1.